Shilpa Antibiotics Ltd was incorporated as a Private Limited Company in November 1987. The commercial production of the Company had started in November 1989. The Company was initially producing Trimethoprim IP/BP, an antibiotic bulk drug. The technology for the bulk drug was developed in house. During the first year of its operation the Company had installed production facilities to manufacture Trimethoprim Apart from selling on its own, the Company had also started manufacturing the product for other reputed Companies like Eskayef Limited, Bombay Drugs and Pharmas Limited, Bombay Drug House Ltd., US Vitamins Ltd, Sandoz India Ltd etc for their export commitments. During 1992, the Company had installed production facilities for manufacture of Sodium Methoxide. The technology for the same had also been developed in house. During the same year the Company secured Export orders from Stellar Exports Limited, Glaxo Limited and Deepak Nitrite Limited for Trimethoprim. Since then the company has started exporting on its own. The Company thus started manufacturing for both export and domestic markets since 1992. It has obtained World Health Organisation-Good Manufacturing Practices (GMP) Certificate. It has also been exporting its products to hard currency areas. The Company now proposes to embark upon an expansion project which involves the addition of one more bulk drug to its existing product range viz; Norfloxcin and expansion of the production capacity of the existing product of the Company viz; Sodium Methoxide and Trimethoprim. The Company also proposes to manufacture 1-Methyl Amino-1-Methyl Thio-2-Nitro Ethane, a drug intermediate, used in the manufacture of Ranitidine, an anti-ulcer drug. To raise the necessary resources to finance the expansion project of the Company, the Company was converted into a Public Limited Company in November 1993. As the company's sales are comparatively more in the September to March period, therefore, to reduce the administrative bottlenecks in the timely preparation of annual results, the company changed its accounting year from March end to September end. Objects of the Company The relevant objects of the company as set out in the memorandum of association of the company are : Main Objects 1. To carry on in India or elsewhere the industry, trade or business of manufacturers, Traders, Dealers, Agents, Suppliers, Licensors, Licensees, Loan Licenses, Importers, Exporters, Consultants, Discoverers, Inventors, and Producers of Drugs, Bulk Drugs, Pharmaceuticals, Pharmaceutical Formulations, Alcohol, Bended Laboratory Preparations, and general medicinal preparation and or their by-products and packing and re-packing of the above. 2007 -Shilpa Medicare Ltd has entered into a memorandum of understanding (MoU) with LOBA Finchemie AG, Austria, to acquire 100% shares of LOBA in an all-cash deal. - The Company has splits its face value from Rs10/- to Rs2/-. 2008 -Shilpa Medicare Ltd has informed that the Board of Director of the Company has co-opted Mr. Sunki Rajendra reddy S/o. Mr Rajeshwara Reddy as an Additional Director. -Shilpa Medicare Ltd has informed that the Board of Directors of the Company has co-opted Mr. N P S Shinh S/o. Mr. S Prithipal Singh Shinh as an Additional Director. 2009 - Shilpa Medicare Ltd has informed that the Company has signed a MOU to form a joint venture company to manufacture drugs and pharmaceuticals with ICE S.r.l. and PCA S.p.a. of Italy. 2010 -Shilpa Medicare Limited has been granted certificate of GMP Compliance of Manufacturer for Gemcitabine Hydrochloride. 2011 -"Shilpa Medicare Ltd acquired Controlling Stake in Nu Therapeutics". 2012 -Shilpa Medicare Ltd has been conferred First Prize of the National Energy Conservation Award-2012 in the Drugs & Pharmaceuticals Sector from Ministry of Power, New Delhi. - The Board also recommended a dividend of 65% i.e. Re. 1.30 (Rupee One & Thirty Paise Only) per equity share of Rs. 2/- each. - Shilpa Medicare Limited (SML) produced five key HIV medicines i.e. Tenofovir, Emtricitabine, Cobicistat, Elvitegravir and a combination of the four, known as "the Quad" for sale in over 100 countries, depending on the medicine. - Shilpa Medicare Ltd has announced the Companys State of art facility at Pharma Park Jadcherla (SEZ), near Mahaboobnagar (AP) for undertaking "Contract Research & Forward Integration i.e. Own Formulation" (Manufacturing of Oral & Injectible (Onco Products) has started functioning partially. 2013 - The Board also recommended a dividend of 65% i.e. Re. 1.30 (Rupee One & Thirty Paise Only) per equity share of Rs. 2/- each. - Shilpa Medicare Limited (SML) produced five key HIV medicines i.e. Tenofovir, Emtricitabine, Cobicistat, Elvitegravir and a combination of the four, known as "the Quad" for sale in over 100 countries, depending on the medicine. - Shilpa Medicare Ltd has announced the Companys State of art facility at Pharma Park Jadcherla (SEZ), near Mahaboobnagar (AP) for undertaking "Contract Research & Forward Integration i.e. Own Formulation" (Manufacturing of Oral & Injectible (Onco Products) has started functioning partially. 2014 - The Company has recommended a dividend of Re. 1/- (One) per equity share of Rs. 2/- (Two) each (i.e. 50%). 2015 -India Pharma Awards 2015 Shilpa Medicare Ltd bagged UBM's Excellence in R&D Award -EUGMP received from Government of Upper Bavaria, Germany for Gemcitabine, Irinotecan HCl, Oxaliplatin and Temozolomide -Shilpa Medicare Ltd bagged Pharmexcil's Patent Award for securing the most number of product patents. -Shilpa Medicare has benchmarked its quality processes against the world's best quality standards in various areas of operation --Shilpa Medicare has splits its face value from Rs. 2 to Rs. 1 2016 -The Company be shifted from Plot No.10, Shop No.80, Rajendra Gunj, Raichur Karnataka- 584102 to #12-6-214/A1, Hyderabad Road, Raichur, Karnataka-584135 with effect from May 03, 2016. -Shilpa Medicare to merge Navya Biologicals with itself 2017 -The company has said that the scheme of merger of Navya Biologicals Private Limited with Shilpa Medicare Limited has been approved by the Hon'ble National Company Law Tribunal, 2019 -Shilpa Medicare gets USFDA nod for cancer drug 2020 -Shilpa Medicare Ltd. launches first affordable generic drug to treat advanced kidney cancer -Shilpa Medicare launches anti-cancer drug - IBRUSHIL 2021- Shilpa Medicare ties up with Cadila Healthcare for production of ZyCoV-D vaccine.-Shilpa Medicare arm inks pact with Dr Reddy"s to manufacture Sputnik V vaccine.-Shilpa Medicare gets tentative USFDA nod for Apremilast tablets.-Shilpa Medicare Ltd has received " Best District Export Excellence Award" from FKCCI.2022-Shilpa Medicare Limited (SML) Received Noc From RCGM, Dept. Of Biotechnology For Its Biosimilar Afliberce.-The Prestigious PEL -HEMSI AWARD presented to Polymer Research & Technology Group of Shilpa Medicare Limited.2023-Shilpa Medicare Limited has launched ORAALr for the first time in India.-Shilpa Medicare's New Drug Application for Pemetrexed Injection 1000 mg/100 ml, 500 mg/50 ml & 100 mg/10 ml, Ready to Use formulation is approved by US FDA. 2020 -Shilpa Medicare launched anti-cancer drug - IBRUSHIL. -Shilpa Medicare launched cancer drug at monthly therapy cost of Rs 6,440. 2021 -Shilpa Medicare ties up with Cadila Healthcare for production of ZyCoV-D vaccine. -'Shilpa Medicare Limited ties up with Dr. Reddy s Laboratories Limited for production of Sputnik V vaccine'. -Shilpa Medicare launches Sunitinib Capsules under brand name SINISHIL. 2024 - Shilpa Medicare receives marketing authorization from Germany for Amifampridine tablets.